[go: up one dir, main page]

WO2020165807A1 - Solid forms of deutetrabenazine and process for the preparation thereof - Google Patents

Solid forms of deutetrabenazine and process for the preparation thereof Download PDF

Info

Publication number
WO2020165807A1
WO2020165807A1 PCT/IB2020/051164 IB2020051164W WO2020165807A1 WO 2020165807 A1 WO2020165807 A1 WO 2020165807A1 IB 2020051164 W IB2020051164 W IB 2020051164W WO 2020165807 A1 WO2020165807 A1 WO 2020165807A1
Authority
WO
WIPO (PCT)
Prior art keywords
deutetrabenazine
vanillin
crystal
solvent
preparation
Prior art date
Application number
PCT/IB2020/051164
Other languages
French (fr)
Inventor
Shanmukha Prasad Gopi
Jayprakash Amarpal YADAV
Satyanarayana THIRUNAHARI
Original Assignee
Dr. Reddy's Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Laboratories Limited filed Critical Dr. Reddy's Laboratories Limited
Publication of WO2020165807A1 publication Critical patent/WO2020165807A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C07C47/58—Vanillin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • aspects of the present application provides co-crystals of Deutetrabenazine and Vanillin, process for the preparation of co-crystals and pharmaceutical composition comprising said co-crystals of Deutetrabenazine.
  • Deutetrabenazine or d 6 -tetrabenazine is a deuterated analog of tetrabenazine.
  • the drug compound having the adopted name “Deutetrabenazine” has chemical name: (RR, SS)-1, 3, 4, 6, 7, 1 lb-hexahydro- 9, 10-di(methoxy-d 3 )-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-one.
  • Deutetrabenazine is a racemic mixture containing the following structures:
  • AUSTEDOTM (Deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT2) inhibitor for oral administration.
  • AUSTEDOTM was approved as oral tablets (6 mg, 9 mg, and 12 mg) by USFDA on 3 April 2017 for the treatment of chorea associated with Huntington’s disease. In August 2017 it was also approved for the treatment of tardive dyskinesia in adults.
  • US8524733B 1 discloses Deutetrabenazine or a pharmaceutically acceptable salt thereof, method for the treatment of chronic hyperkinetic movement disorders and pharmaceutical composition thereof.
  • US9550780B2 discloses crystalline Form I and crystalline Form II of Deutetrabenazine .
  • WO2017221169A1 discloses premixes of deutetrabenazine with polyvinylpyrrolidone K-30, copovidone, talc and magnesium stearate.
  • WO2019166962 A1 discloses crystalline Form Ml of Deutetrabenzine.
  • US 20190343815A1 disclose Deutetrabenazine Form APO-I, a co-crystal of Deutetrabenazine and quercetin, and Deutetrabenazine Form APO-II, a co crystal of Deutetrabenazine and luteolin.
  • polymorphism The occurrence of different crystal forms, i.e., polymorphism, is a property of some compounds.
  • a single molecule may give rise to a variety of polymorphs having distinct crystal structures and physical properties, such as PXRD patterns, IR absorption spectra, melting points (MP), TGA curves, DSC curves, and solubilities.
  • Polymorphs are different solids having the same molecular structure, yet having distinct physical properties when compared to other polymorphs of the same structure.
  • the present application provides co-crystal of Deutetrabenazine and Vanillin, process of preparing said co-crystal and pharmaceutical composition comprising said co-crystal and one or more pharmaceutically acceptable excipients.
  • the pharmaceutical composition is in the form of a solid dosage form.
  • the pharmaceutical composition is a tablet.
  • Figure 1 illustrates a characteristic PXRD pattern of co-crystal of Deutetrabenazine and Vanillin obtained from example 1.
  • Figure 2 illustrates a comparative PXRD pattern of co-crystal of Deutetrabenazine and Vanillin and simulated PXRD pattern obtained from single crystal data.
  • Figure 3 illustrates a single Crystal structure of co-crystal of Deutetrabenazine and Vanillin.
  • Figure 4 illustrates a characteristic DSC thermogram of co-crystal of Deutetrabenazine and Vanillin.
  • Figure 5 illustrates a characteristic TGA thermogram of co-crystal of Deutetrabenazine and Vanillin.
  • Figure 6 illustrates a characteristic PXRD pattern of co-crystal of Deutetrabenazine and Vanillin obtained from example 2.
  • the co-crystal of Deutetrabenazine and Vanillin characterized by a PXRD pattern having X-ray powder diffraction peaks selected from the following at about 8.34°, 9.45°, 14.08° and 15.85° ⁇ 0.2°2Q is designated as Form DV 1.
  • the application provides co-crystal of Deutetrabenazine and Vanillin, characterized by an X-ray powder diffraction pattern as illustrated in Figure 1.
  • the present application provides process for the preparation of co-crystal of Deutetrabenazine and Vanillin by dissolving Deutetrabenazine and Vanillin in a suitable solvent and cooling the obtained solution.
  • any suitable solvent can be used for preparing solution.
  • the suitable solvents can be selected from ketones, alcohols, esters, nitriles, or their mixtures.
  • the solution of Deutetrabenazine and Vanillin may be obtained by heating and stirring at suitable temperature. In embodiments the solution of Deutetrabenazine and Vanillin may be filtered to get particle free solution. In embodiments the seed of co-crystals of Deutetrabenazine and Vanillin may also be used for preparing product. The solution may be cooled to get precipitation at a temperature about -10 to 30°C, preferably about 0 to 25°C. The precipitated product may be isolated by filtration and dried at suitable temperature.
  • the present application provides process for the preparation of co-crystal of Deutetrabenazine and Vanillin, comprising the steps of; taking Deutetrabenazine and Vanillin into ball-milling capsule, adding acetonitrile in to it and grinding to obtain the Vanillin co-crystal of Deutetrabenazine .
  • the present application provides process for the preparation of co-crystal of Deutetrabenazine and Vanillin comprising;
  • step (a) adding the anti-solvent to the solution obtained in step (a);
  • any suitable solvent can be used for preparing solution.
  • the suitable solvents can be selected from ketones, alcohols, esters, nitriles, or their mixtures.
  • anti- solvent is added to solution obtained in step a).
  • the anti-solvent can be a solvent in which Deutetrabenazine is insoluble or having very poor solubility.
  • the anti-solvent can be selected from ethers, alkanes, cycloalkanes or mixtures thereof.
  • the anti- solvent can be a mixture of Methyl t-butyl ether and n- Heptane. In embodiments both anti- solvents can be added together or simultaneously.
  • Methyl t-butyl ether was added to the solution of step a) followed by addition of n-Heptane.
  • the ratio of solvent to anti-solvents can be in the range of 1:5 to 1:100 or preferably 1:5 to 1: 50 or any suitable combination.
  • the ratio of anti- solvents Methyl t-butyl ether and n-Heptane can be in the range of 1:1 to 1:10 or any suitable combination.
  • the seed of co-crystals of Deutetrabenazine and Vanillin may also be used for preparing product.
  • co-crystals of Deutetrabenazine and Vanillin according to the present application can be milled or micronized by any process known in the art, such as ball milling, jet milling, wet milling etc., to produce desired particle sizes and particle size distributions.
  • Single crystal X-ray structure of Deutetrabenazine and Vanillin reveals that the asymmetric unit consists of one molecule of Deutetrabenazine and one molecule of Vanillin. It is a 1:1 stoichiometric anhydrous co-crystal.
  • the single crystal structure of co-crystal of Deutetrabenazine and Vanillin is illustrated in Figure-3.
  • the co-crystals of Deutetrabenazine and Vanillin has a differential scanning calorimetric thermogram (DSC) substantially as shown in Figure. 4, which exhibits an endothermic peak at about 101.16°C.
  • DSC differential scanning calorimetric thermogram
  • the co-crystals of Deutetrabenazine and Vanillin has a thermal gravimetric analysis thermogram substantially as shown in Figure. 5.
  • the co-crystals of Deutetrabenazine and Vanillin is non-hygroscopic, chemically and physically stable and suitable for pharmaceutical formulation.
  • the following table provides the stability data of co-crystals of Deutetrabenazine and Vanillin.
  • Vanillin used in the present application is an organic compound with the molecular formula CsHsC and represented by the chemical structure;
  • Deutetrabenazine may be prepared by the processes described in US8524733B 1, US9550780B2, WO2015084622A1, WO2011153157A2 and WO2017182916A1.
  • the present application provides a pharmaceutical composition comprising the co-crystals of Deutetrabenazine and Vanillin as described in the present application together with at least one pharmaceutically acceptable excipient.
  • the pharmaceutical composition is a solid dosage form suitable for oral administration, such as a capsule, tablet, pill, powder or granulate.
  • the pharmaceutical composition is a tablet.
  • the pharmaceutical composition provides a dose of Deutetrabenazine that is equivalent to the 6 mg, 9 mg or 12 mg of Deutetrabenazine found in AUSTEDO® drug products.
  • Suitable pharmaceutically acceptable excipients are preferably inert with respect to the co-crystal of Deutetrabenazine and Vanillin of the present invention, and may include, for example, one or more excipients selected from binders such as lactose, starches, modified starches, sugars, gum acacia, gum tragacanth, guar gum, pectin, wax binders, microcrystalline cellulose, methylcellulose, carboxymethylcellulose, hydro xypropyl methylcellulose, hydroxy ethyl cellulose, hydroxypropyl cellulose, copolyvidone, gelatine, polyvinylpyrollidone (PVP) and sodium alginate; fillers or diluents such as lactose, sugar, starches, modified starches, mannitol, sorbitol, inorganic salts, cellulose derivatives (e.g., microcrystalline cellulose, cellulose), calcium sulphate, xylitol and lacti
  • excipients including preservatives, stabilisers, anti-oxidants, silica flow conditioners, antiadherents or glidants may be added as required.
  • suitable excipients and the preparation of solid oral dosage forms is well known to person of skill in the art, and is described generally, for example, in Remington The Science and Practice of Pharmacy 21st Edition (Lippincott Williams & Wilkins: Philadelphia; 2006; Chapter 45).
  • the solid dosage forms may be prepared with coatings, such as enteric coatings and extended release coatings, using standard pharmaceutical coatings.
  • coatings such as enteric coatings and extended release coatings, using standard pharmaceutical coatings.
  • Such coatings, and their application are well known to persons skilled in the art, and are described, for example, in Remington The Science and Practice of Pharmacy 21st Edition (Lippincott Williams & Wilkins: Philadelphia; 2006; Chapter 47).
  • Heating rate 10° C per minute.
  • Heating rate 10° C. per minute.
  • Purge gas nitrogen.
  • Example-1 Preparation of co-crystal of Deutetrabenazine and Vanillin
  • Deutetrabenazine (1.616 g), Vanillin (0.760) and ethylformate (8 mL) were taken into taken into EasyMax reactor and stirred at 50°C to get clear solution.
  • the clear solution was cooled to 35°C and seed material (100 mg) was added.
  • the obtained suspension was stirred for 2 h at 25°C.
  • the precipitated product was filtered to obtain the co-crystal of Deutetrabenazine and Vanillin.
  • Deutetrabenazine (300 mg) and Vanillin (141 mg) were taken into ball- milling capsule and added 1 ml of Acetonitrile and kept for grinding with 25 RPM for 1 h to obtain the co-crystal of Deutetrabenazine and Vanillin.
  • the PXRD pattern of the isolated material is represented as Figure-6.
  • Deutetrabenazine (970 mg), Vanillin (456 mg) and acetonitrile (6 mL) were taken into EasyMax reactor and stirred for 1 h at 50°C to clear get solution. The temperature was reduced to 40°C and seed material was added to the solution. The solution was gradually cooled to 25°C. The precipitated product was filtered to obtain the co-crystal of Deutetrabenazine and Vanillin.
  • Deutetrabenazine (323 mg), Vanillin (152 mg) and acetonitrile (3 mL) were taken into EasyMax reactor and stirred for 20 min at 45°C to get clear solution. The solution was filtered to get particle free solution. Methyl t-butyl ether (10 mL) and n-Heptane (15 mL) were added to the clear solution under stirring. The solution was kept overnight for evaporation of solvent. The title product was obtained by filtration.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides co-crystals of Deutetrabenazine and Vanillin, process for the preparation of co-crystals and pharmaceutical composition comprising said co-crystals of Deutetrabenazine. The co-crystals of Deutetrabenazine and Vanillin is non-hygroscopic, chemically and physically stable and suitable for pharmaceutical formulation and its use in the treatment of tardive dyskinesia and chorea associated with Huntington's disease.

Description

SOLID FORMS OF DEUTETRABENAZINE AND PROCESS FOR THE
PREPARATION THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of Indian provisional patent application No. 201941005900 filed on 14 February 2019; Indian provisional patent application No. 201941011996 filed on 27 March 2019.
INTRODUCTION
Aspect of the present application provides co-crystals of Deutetrabenazine and Vanillin, process for the preparation of co-crystals and pharmaceutical composition comprising said co-crystals of Deutetrabenazine.
Deutetrabenazine or d6-tetrabenazine is a deuterated analog of tetrabenazine. The drug compound having the adopted name “Deutetrabenazine” has chemical name: (RR, SS)-1, 3, 4, 6, 7, 1 lb-hexahydro- 9, 10-di(methoxy-d3)-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-one.
Deutetrabenazine is a racemic mixture containing the following structures:
Figure imgf000002_0001
55- Deutetrabenazine 55- Deutetrabenazine
AUSTEDO™ (Deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT2) inhibitor for oral administration. AUSTEDO™ was approved as oral tablets (6 mg, 9 mg, and 12 mg) by USFDA on 3 April 2017 for the treatment of chorea associated with Huntington’s disease. In August 2017 it was also approved for the treatment of tardive dyskinesia in adults.
US8524733B 1 discloses Deutetrabenazine or a pharmaceutically acceptable salt thereof, method for the treatment of chronic hyperkinetic movement disorders and pharmaceutical composition thereof. US9550780B2 discloses crystalline Form I and crystalline Form II of Deutetrabenazine .
WO2017221169A1 discloses premixes of deutetrabenazine with polyvinylpyrrolidone K-30, copovidone, talc and magnesium stearate.
WO2019166962 A1 discloses crystalline Form Ml of Deutetrabenzine. US 20190343815A1 disclose Deutetrabenazine Form APO-I, a co-crystal of Deutetrabenazine and quercetin, and Deutetrabenazine Form APO-II, a co crystal of Deutetrabenazine and luteolin.
The occurrence of different crystal forms, i.e., polymorphism, is a property of some compounds. A single molecule may give rise to a variety of polymorphs having distinct crystal structures and physical properties, such as PXRD patterns, IR absorption spectra, melting points (MP), TGA curves, DSC curves, and solubilities. Polymorphs are different solids having the same molecular structure, yet having distinct physical properties when compared to other polymorphs of the same structure.
The discovery of new polymorphs and solvates of a pharmaceutical active compound provides an opportunity to improve the performance of a drug product in terms of its bio availability or release profile in vivo, or it may have improved stability or advantageous handling properties. Polymorphism is an unpredictable property of any given compound. This subject has been reviewed in recent articles, including A. Goho,“Tricky Business,” Science News, August 21, 2004. In general, one cannot predict whether there will be more than one form for a compound, how many forms will eventually be discovered, or how to prepare any previously unidentified form.
There remains a need to provide the new polymorphic forms of Deutetrabenazine which can be used in the pharmaceutical composition.
SUMMARY OF THE INVENTION
The present application provides co-crystal of Deutetrabenazine and Vanillin, process of preparing said co-crystal and pharmaceutical composition comprising said co-crystal and one or more pharmaceutically acceptable excipients. Preferably, the pharmaceutical composition is in the form of a solid dosage form. Most preferably, the pharmaceutical composition is a tablet.
BRIEF DESCRIPTION OF THE DRAWING
Figure 1 illustrates a characteristic PXRD pattern of co-crystal of Deutetrabenazine and Vanillin obtained from example 1.
Figure 2 illustrates a comparative PXRD pattern of co-crystal of Deutetrabenazine and Vanillin and simulated PXRD pattern obtained from single crystal data.
Figure 3 illustrates a single Crystal structure of co-crystal of Deutetrabenazine and Vanillin.
Figure 4 illustrates a characteristic DSC thermogram of co-crystal of Deutetrabenazine and Vanillin.
Figure 5 illustrates a characteristic TGA thermogram of co-crystal of Deutetrabenazine and Vanillin.
Figure 6 illustrates a characteristic PXRD pattern of co-crystal of Deutetrabenazine and Vanillin obtained from example 2.
DETAILED DESCRIPTION
In an aspect, the co-crystal of Deutetrabenazine and Vanillin characterized by a PXRD pattern having X-ray powder diffraction peaks selected from the following at about 8.34°, 9.45°, 14.08° and 15.85°± 0.2° 2Q and it may be further characterized by X-ray powder diffraction peaks at about 10.01°, 16.94° and 23.78° ± 0.2° 2Q. In an aspect, the co-crystal of Deutetrabenazine and Vanillin characterized by a PXRD pattern having X-ray powder diffraction peaks selected from the following at about 8.34°, 9.45°, 14.08° and 15.85°± 0.2°2Q is designated as Form DV 1.
In another aspect, the application provides co-crystal of Deutetrabenazine and Vanillin, characterized by an X-ray powder diffraction pattern as illustrated in Figure 1.
In another aspect, the present application provides process for the preparation of co-crystal of Deutetrabenazine and Vanillin by dissolving Deutetrabenazine and Vanillin in a suitable solvent and cooling the obtained solution.
In embodiments any suitable solvent can be used for preparing solution. The suitable solvents can be selected from ketones, alcohols, esters, nitriles, or their mixtures.
In embodiments the solution of Deutetrabenazine and Vanillin may be obtained by heating and stirring at suitable temperature. In embodiments the solution of Deutetrabenazine and Vanillin may be filtered to get particle free solution. In embodiments the seed of co-crystals of Deutetrabenazine and Vanillin may also be used for preparing product. The solution may be cooled to get precipitation at a temperature about -10 to 30°C, preferably about 0 to 25°C. The precipitated product may be isolated by filtration and dried at suitable temperature.
In another aspect, the present application provides process for the preparation of co-crystal of Deutetrabenazine and Vanillin, comprising the steps of; taking Deutetrabenazine and Vanillin into ball-milling capsule, adding acetonitrile in to it and grinding to obtain the Vanillin co-crystal of Deutetrabenazine .
In another aspect, the present application provides process for the preparation of co-crystal of Deutetrabenazine and Vanillin comprising;
a) dissolving Deutetrabenazine and Vanillin in a solvent;
b) adding the anti-solvent to the solution obtained in step (a); and
c) isolating the co-crystal of Deutetrabenazine and Vanillin.
In embodiments any suitable solvent can be used for preparing solution. The suitable solvents can be selected from ketones, alcohols, esters, nitriles, or their mixtures.
In embodiment of step b), anti- solvent is added to solution obtained in step a). The anti-solvent can be a solvent in which Deutetrabenazine is insoluble or having very poor solubility. In embodiments the anti-solvent can be selected from ethers, alkanes, cycloalkanes or mixtures thereof. In embodiments the anti- solvent can be a mixture of Methyl t-butyl ether and n- Heptane. In embodiments both anti- solvents can be added together or simultaneously. In embodiments Methyl t-butyl ether was added to the solution of step a) followed by addition of n-Heptane. In embodiments the ratio of solvent to anti-solvents can be in the range of 1:5 to 1:100 or preferably 1:5 to 1: 50 or any suitable combination. In embodiments the ratio of anti- solvents Methyl t-butyl ether and n-Heptane can be in the range of 1:1 to 1:10 or any suitable combination.
In embodiments the seed of co-crystals of Deutetrabenazine and Vanillin may also be used for preparing product.
In embodiments, co-crystals of Deutetrabenazine and Vanillin according to the present application can be milled or micronized by any process known in the art, such as ball milling, jet milling, wet milling etc., to produce desired particle sizes and particle size distributions.
Single crystal X-ray structure of Deutetrabenazine and Vanillin reveals that the asymmetric unit consists of one molecule of Deutetrabenazine and one molecule of Vanillin. It is a 1:1 stoichiometric anhydrous co-crystal. The single crystal structure of co-crystal of Deutetrabenazine and Vanillin is illustrated in Figure-3.
Crystal data and structure refinement of Deutetrabenazine and Vanillin 1:1 co-crystal.
Figure imgf000006_0001
Figure imgf000007_0001
The co-crystals of Deutetrabenazine and Vanillin has a differential scanning calorimetric thermogram (DSC) substantially as shown in Figure. 4, which exhibits an endothermic peak at about 101.16°C.
The co-crystals of Deutetrabenazine and Vanillin has a thermal gravimetric analysis thermogram substantially as shown in Figure. 5.
The co-crystals of Deutetrabenazine and Vanillin is non-hygroscopic, chemically and physically stable and suitable for pharmaceutical formulation. The following table provides the stability data of co-crystals of Deutetrabenazine and Vanillin.
Table-1 Stability data of co-crystals of Deutetrabenazine and Vanillin
Figure imgf000007_0002
Figure imgf000008_0002
Vanillin used in the present application is an organic compound with the molecular formula CsHsC and represented by the chemical structure;
Figure imgf000008_0001
Any physical form of Deutetrabenazine may be utilized for preparing the co-crystal of the present application. For example Deutetrabenazine may be prepared by the processes described in US8524733B 1, US9550780B2, WO2015084622A1, WO2011153157A2 and WO2017182916A1.
In another aspect, the present application provides a pharmaceutical composition comprising the co-crystals of Deutetrabenazine and Vanillin as described in the present application together with at least one pharmaceutically acceptable excipient. Preferably, the pharmaceutical composition is a solid dosage form suitable for oral administration, such as a capsule, tablet, pill, powder or granulate. Most preferably, the pharmaceutical composition is a tablet. Preferably, the pharmaceutical composition provides a dose of Deutetrabenazine that is equivalent to the 6 mg, 9 mg or 12 mg of Deutetrabenazine found in AUSTEDO® drug products.
Suitable pharmaceutically acceptable excipients are preferably inert with respect to the co-crystal of Deutetrabenazine and Vanillin of the present invention, and may include, for example, one or more excipients selected from binders such as lactose, starches, modified starches, sugars, gum acacia, gum tragacanth, guar gum, pectin, wax binders, microcrystalline cellulose, methylcellulose, carboxymethylcellulose, hydro xypropyl methylcellulose, hydroxy ethyl cellulose, hydroxypropyl cellulose, copolyvidone, gelatine, polyvinylpyrollidone (PVP) and sodium alginate; fillers or diluents such as lactose, sugar, starches, modified starches, mannitol, sorbitol, inorganic salts, cellulose derivatives (e.g., microcrystalline cellulose, cellulose), calcium sulphate, xylitol and lactitol; disintegrants such as croscarmellose sodium, crospovidone, polyvinylpyrrolidone, sodium starch glycollate, corn starch, microcrystalline cellulose, hydroxypropyl methylcellulose and hydroxypropyl cellulose; lubricants such as magnesium stearate, magnesium lauryl stearate, sodium stearyl fumarate, stearic acid, calcium stearate, zinc stearate, potassium benzoate, sodium benzoate, myristic acid, palmitic acid, mineral oil, hydrogenated castor oil, medium-chain triglycerides, poloxamer, polyethylene glycol and talc; and dispersants or solubility enhancing agents, such cyclodextrins, glyceryl monostearate, hypromellose, meglumine, Poloxamer, polyoxyethylene castor oil derivatives, polyoxyethylene stearates, polyoxylglycerides, povidone, and stearic acid. Other excipients including preservatives, stabilisers, anti-oxidants, silica flow conditioners, antiadherents or glidants may be added as required. Other suitable excipients and the preparation of solid oral dosage forms is well known to person of skill in the art, and is described generally, for example, in Remington The Science and Practice of Pharmacy 21st Edition (Lippincott Williams & Wilkins: Philadelphia; 2006; Chapter 45).
Optionally, when the pharmaceutical compositions are solid dosage forms, the solid dosage forms may be prepared with coatings, such as enteric coatings and extended release coatings, using standard pharmaceutical coatings. Such coatings, and their application, are well known to persons skilled in the art, and are described, for example, in Remington The Science and Practice of Pharmacy 21st Edition (Lippincott Williams & Wilkins: Philadelphia; 2006; Chapter 47).
Certain specific aspects and embodiments of the present application will be explained in greater detail with reference to the following examples, which are provided only for purposes of illustration and should not be construed as limiting the scope of the application in any manner. Variations of the described procedures, as will be apparent to those skilled in the art, are intended to be within the scope of the present application.
The term "about" when used in the present application preceding a number and referring to it, is meant to designate any value which lies within the range of ±10%, preferably within a range of ±5%, more preferably within a range of ±2%, still more preferably within a range of ±1 % of its value. For example "about 10" should be construed as meaning within the range of 9 to 11, preferably within the range of 9.5 to 10.5, more preferably within the range of 9.8 to 10.2, and still more preferably within the range of 9.9 to 10.1.
General description of the PXRD equipment
All PXRD data reported herein are obtained using a PANalytical X-ray Diffractometer, with copper Ka radiation.
Instrumental parameters.
Figure imgf000010_0001
Figure imgf000011_0001
Differential Scanning Calorimetry (DSC)
Analytical Instrument: TA Instruments Discovery (DSC)
Heating rate: 10° C per minute.
Purge gas: nitrogen
Thermal Gravimetric Analysis (TGA)
Analytical Instrument: TA Instruments Q500 (TGA)
Heating rate: 10° C. per minute.
Purge gas: nitrogen.
EXAMPLES
Example-1: Preparation of co-crystal of Deutetrabenazine and Vanillin
Deutetrabenazine (1.616 g), Vanillin (0.760) and ethylformate (8 mL) were taken into taken into EasyMax reactor and stirred at 50°C to get clear solution. The clear solution was cooled to 35°C and seed material (100 mg) was added. The obtained suspension was stirred for 2 h at 25°C. The precipitated product was filtered to obtain the co-crystal of Deutetrabenazine and Vanillin.
Yield: 1.9 g
The PXRD pattern of the isolated material is represented as Figure- 1. Example-2: Preparation of co-crystal of Deutetrabenazine and Vanillin
Deutetrabenazine (300 mg) and Vanillin (141 mg) were taken into ball- milling capsule and added 1 ml of Acetonitrile and kept for grinding with 25 RPM for 1 h to obtain the co-crystal of Deutetrabenazine and Vanillin.
The PXRD pattern of the isolated material is represented as Figure-6.
Example-3: Preparation of co-crystal of Deutetrabenazine and Vanillin
Deutetrabenazine (970 mg), Vanillin (456 mg) and acetonitrile (6 mL) were taken into EasyMax reactor and stirred for 1 h at 50°C to clear get solution. The temperature was reduced to 40°C and seed material was added to the solution. The solution was gradually cooled to 25°C. The precipitated product was filtered to obtain the co-crystal of Deutetrabenazine and Vanillin.
Example-4: Preparation of co-crystal of Deutetrabenazine and Vanillin
Deutetrabenazine (323 mg), Vanillin (152 mg) and acetonitrile (3 mL) were taken into EasyMax reactor and stirred for 20 min at 45°C to get clear solution. The solution was filtered to get particle free solution. Methyl t-butyl ether (10 mL) and n-Heptane (15 mL) were added to the clear solution under stirring. The solution was kept overnight for evaporation of solvent. The title product was obtained by filtration.

Claims

Claims:
1. A co-crystal of Deutetrabenazine and Vanillin.
2. The co-crystal of claim 1, wherein the molar ratio of Deutetrabenazine to Vanillin is 1:1.
3. The co-crystal of claim 1, characterized by a PXRD diffractogram comprising peaks, at 8.34°, 9.45°, 14.08° and 15.85°± 0.2° 2Q.
4. The co-crystal of claim 1, further comprising peaks at 10.01°, 16.94° and 23.78° ± 0.2° 2Q.
5. The co-crystal of claim 1, providing a PXRD diffractogram substantially the same as the PXRD diffractogram provided in Figure 1.
6. A process for the preparation of co-crystal of Deutetrabenazine and Vanillin comprising; dissolving Deutetrabenazine and Vanillin in a suitable solvent and cooling the solution.
7. The process of claim 6, wherein the solvent can be selected from ketones, alcohols, esters, nitriles, or their mixtures.
8. A process for the preparation of co-crystal of Deutetrabenazine and Vanillin comprising the steps of; taking Deutetrabenazine and Vanillin into ball-milling capsule, adding acetonitrile in to it and grinding.
9. A process for the preparation of co-crystal of Deutetrabenazine and Vanillin comprising:
a) dissolving Deutetrabenazine and Vanillin in a solvent;
b) adding the anti-solvent to the solution obtained in step (a); and c) isolating the co-crystal of Deutetrabenazine and Vanillin.
10. The process of claim 9, wherein the solvent in step a) can be selected from ketones, alcohols, esters, nitriles, or their mixtures.
11. The process of claim 9, wherein the anti-solvent in step b) can be selected from ethers, alkanes, cycloalkanes or mixtures thereof.
12. The process of claim 9, wherein the anti-solvent is Methyl t-butyl ether and n-heptane.
13. A pharmaceutical composition comprising a co-crystal of Deutetrabenazine and Vanillin and one or more pharmaceutically acceptable excipients.
14. The pharmaceutical composition of claim 13, wherein the pharmaceutical composition is a tablet.
PCT/IB2020/051164 2019-02-14 2020-02-13 Solid forms of deutetrabenazine and process for the preparation thereof WO2020165807A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201941005900 2019-02-14
IN201941005900 2019-02-14
IN201941011996 2019-03-27
IN201941011996 2019-03-27

Publications (1)

Publication Number Publication Date
WO2020165807A1 true WO2020165807A1 (en) 2020-08-20

Family

ID=72044798

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/051164 WO2020165807A1 (en) 2019-02-14 2020-02-13 Solid forms of deutetrabenazine and process for the preparation thereof

Country Status (1)

Country Link
WO (1) WO2020165807A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180263972A1 (en) * 2017-03-15 2018-09-20 Auspex Pharmaceuticals, Inc. Analogs of deutetrabenazine, their preparation and use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180263972A1 (en) * 2017-03-15 2018-09-20 Auspex Pharmaceuticals, Inc. Analogs of deutetrabenazine, their preparation and use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FRANCOISE M. AMOMBO NOA ET AL.: "Co-crystals and salts of vanillic acid and vanillin with amines", CRYSTENGCOMM, vol. 20, no. 7, 8 January 2018 (2018-01-08), pages 896 - 905, XP055732880 *
LINDA LANGE ET AL.: "Predicting the Solubility of Pharmaceutical Cocrystals in Solvent/Anti-Solvent Mixtures", MOLECULES, vol. 21, no. 5, 7 May 2016 (2016-05-07), pages 1 - 18, XP055732884 *

Similar Documents

Publication Publication Date Title
JP2010280713A (en) Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or solvate thereof, and process for preparing the same
CN105189513A (en) Crystalline forms of d-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3, 5-difluoropyridine-2-yl)-8-chloro-6-fluoro-1, 4-dihydro-7-(3-hydroxyazetidin-1-yl)-4-oxo-3-quinolinecarboxylate
JP2024517431A (en) Solid state forms of (S)-N-(3-(2-(((R)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and its salts
EP4353230A2 (en) Solid state forms of asciminib and process for preparation thereof
WO2016097314A1 (en) Amorphous and crystalline forms of idelalisib and process for forming the same
TWI815820B (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
US10662178B2 (en) Crystalline form of Olaparib
HK1248224A1 (en) Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof
US11236066B2 (en) Crystalline forms of niraparib tosylate
US11072620B2 (en) Crystalline forms of Ponatinib hydrochloride
JP2019509306A (en) Crystalline form of drug hydrochloride used for treatment or prevention of JAK-related diseases and method for producing the same
WO2020165807A1 (en) Solid forms of deutetrabenazine and process for the preparation thereof
JP2013543495A (en) Solid forms of potent HCV inhibitors
US20200317616A1 (en) Crystalline Form of Betrixaban Maleate
US10611772B2 (en) Crystalline form of Ribociclib succinate
CN111320596A (en) Mefurapiride hydrochloride polymorph and preparation method thereof
US20240116884A1 (en) Salts of Viloxazine
US20250223295A1 (en) Solid state forms of rucaparib tosylate
US10632107B2 (en) Crystalline forms of benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2022253261A1 (en) Hydrate crystal form of lazertinib methanesulfonate, preparation method therefor and use thereof
WO2025133072A1 (en) Crystalline forms of elacestrant dihydrochloride
WO2024176164A1 (en) Solid state form of pirtobrutinib
CN116836132A (en) A kind of vortioxetine hydrobromide crystal form H and its preparation method and use
HK1213549B (en) Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20756713

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20756713

Country of ref document: EP

Kind code of ref document: A1